ArticleCell death and differentiation2026
MEGF8 controls osteogenic differentiation through post-transcriptional regulation of BMP-SMAD signaling in craniosynostosis.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Carpenter syndrome, caused by biallelic mutations in MEGF8 or RAB23, manifests with craniosynostosis through incompletely defined mechanisms. While both genes encode negative regulators of Hedgehog (Hh) signaling, we demonstrate that MEGF8 maintains cranial suture patency through a distinct, Hh-independent pathway. Loss of MEGF8 disrupts ubiquitination and lysosomal degradation of BMPR1A, leading to BMPR1A accumulation and hyperactivation of canonical BMP-SMAD1/5/9 signaling, which accelerates osteogenic differentiation of cranial mesenchyme. Using Megf8 mutant mice, we show tissue-specific specialization: limb defects are Hh-dependent and rescued by SMO inhibition, whereas craniosynostosis is BMP-driven and refractory to Hh blockade, with BMP type I receptor inhibition selectively rescuing the cranial phenotype. Comparative analyses reveal that MEGF8 and RAB23 promote osteogenic differentiation through distinct mechanisms-MEGF8 via ubiquitin-mediated BMPR1A turnover and BMP-SMAD activation, RAB23 through FGF-ERK signaling-despite both affecting GLI1-mediated transcription. Reintroduction of human MEGF8 in MEGF8-knockdown cells restores BMPR1A protein levels, validating the specificity of MEGF8-mediated BMPR1A regulation. These findings suggest that MEGF8 modulates BMP signaling post-transcriptionally, establishes tissue-specific regulatory mechanisms in syndromic disorders, and demonstrates how divergent pathways converge on shared phenotypes, with implications for pathway-specific therapeutic strategies.
Identifiers
42399640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.